Frequency and Mutation Patterns of Resistance in Patients with Chronic Hepatitis B Infection Treated with Nucleos(t)ide Analogs in Add-On and Switch Strategies

Hepatitis Monthly

Volumn 11, Issue 10, 2011, Pages 835-842

  Sayan, Murat ^a   Akhan, Sila Cetin ^a   Senturk, Omer ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Hepatitis B Virus; Mutation; Nucleoside; Therapeutics

Indexed keywords

EID: 84871492863     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/kowsar.1735143X.775     Document Type: Article

References (48)

1. Mittal A, Airon RK, Magu S, Rattan KN, Ratan SK. Associated anomalies with anorectal malformation (ARM). Indian J Pediatr. 2004;71(6):509-14.
2. Delaney WEt, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vi-tro. J Virol. 2003;77(21):11833-41.
3. Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiol. 2008;3(5):525-38.
4. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-42.
5. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26(2):162-70.
6. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resis-tance: mechanisms, detection and interpretation. J Hepatol. 2006;44(3):593-606.
7. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat. 2006;13(7):427-34.
8. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528-36.
9. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lami-vudine. Antimicrob Agents Chemother. 2004;48(9):3498-507.
10. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenter-ology. 2003;125(2):292-7.
11. Bartholomeusz A, Locarnini S, Ayres A, Thompson G, Sozzi V, Angus P, et al. Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology. 2004;40(Suppl 1):246A.
12. Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, et al. SeqHepB: a sequence analysis program and relational data-base system for chronic hepatitis B. Antiviral Res. 2007;75(1):64-74.
13. Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Es-teban R, et al. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat. 2007;14(12):835-40.
14. Sertoz RY, Erensoy S, Pas S, Akarca US, Ozgenc F, Yamazhan T, et al. Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother. 2005;17(5):514-20.
15. Niesters HG, Pas S, de Man RA. Detection of hepatitis B virus gen-otypes and mutants: current status. J Clin Virol. 2005;34 (Suppl 1):S4-8.
16. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol. 2006;78 (Suppl 1):S52-5.
17. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112-25.
18. Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpi-nar H, et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol. 2006;21(12):1783-8.
19. Akyildiz M, Gunsar F, Ersoz G, Karasu Z, Ilter T, Batur Y, et al. Ad-efovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compen-sated chronic hepatitis B. Dig Dis Sci. 2007;52(12):3444-7.
20. Tuncbilek S, Kose S, Elaldi A, Akman S. Lamivudine resistance in untreated chronic hepatitis B patients in Turkey. Turk J Gastroen-terol. 2008;19(2):99-103.
21. Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, Aslan N, Sez-gin O, Sahin T, et al. YSDD: a novel mutation in HBV DNA poly-merase confers clinical resistance to lamivudine. J Viral Hepat. 2003;10(4):256-65.
22. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431-5.
23. Rozanov M, Plikat U, Chappey C, Kochergin A, Tatusova T. A web-based genotyping resource for viral sequences. Nucleic Acids Res. 2004;32(Web Server issue):W654-9.
24. Avellon A, Echevarria JM. Frequency of hepatitis B virus ‘a’ deter-minant variants in unselected Spanish chronic carriers. J Med Virol. 2006;78(1):24-36.
25. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat. 2005;12(4):333-45.
26. Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, et al. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J Viral Hepat. 2009;16(4):279-85.
27. Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, et al. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci. 2011;56(7):2130-6.
28. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother. 2007;51(7):2285-92.
29. Amini-Bavil-Olyaee S, Herbers U, Mohebbi SR, Sabahi F, Zali MR, Luedde T, et al. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. J Hepatol. 2009;51(4):647-54.
30. Sayan M, Akhan SC, Meric M. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat. 2010;17(1):23-7.
31. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2006;44(2):422-31.
32. Sayan M. Molecular Diagnosis of Entecavir Resistance. Hepat Mon. 2010;10(1):42-7.
33. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48(1):99-108.
34. Karatayli E, Karayalcin S, Karaaslan H, Kayhan H, Turkyilmaz AR, Sahin F, et al. A novel mutation pattern emerging during lami-vudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther. 2007;12(5):761-8.
35. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-trans-planted patient. Gastroenterology. 2006;131(4):1253-61.
36. Sayan M, Hulagu S, Karatayli SC. Multidrug-Resistant Hepatitis B Virus Strain in a Chronic Turkish Patient. Hepat Mon. 2010;10(2):141-6.
37. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol. 2002;25(2):97-106.
38. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005;32(2):102-12.
39. Sayan M, Senturk O, Akhan SC, Hulagu S, Cekmen MB. Monitor-ing of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B. Int J Infect Dis. 2010;14 (Suppl 3):e136-41.
40. Locarnini SA. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology. 1998;27(1):294-7.
41. Pei F, Ning JY, You JF, Yang JP, Zheng J. YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplanta-tion. World J Gastroenterol. 2005;11(18):2714-9.
42. Bozdayi AM, Aslan N, Bozdayi G, Turkyilmaz AR, Sengezer T, Wend U, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol. 2004;149(11):2115-29.
43. Sayan M, Hulagu S, Akhan SC, Senturk O, Meric M, Cekmen M. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients]. Mikrobiyol Bul. 2009;43(3):425-32.
44. Sayan M, Akhan SC, Bozdayi M. Genotype A2_adw2 Strain of Hepatitis B Virus in Turkey: A Case Report. Hepat Mon. 2010;10(4):302.
45. Sayan M, Akhan SC. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B. Int J Infect Dis. 2011; 15(10): e 722-6.
46. Leblebicioglu H, Eroglu C. Acute hepatitis B virus infection in Turkey: epidemiology and genotype distribution. Clin Microbiol Infect. 2004;10(6):537-41.
47. Ozdemir FT, Duman D, Ertem D, Avsar E, Eren F, Ozdogan O, et al. Determination of hepatitis B genotypes in patients with chronic hepatitis B virus infection in Turkey. Turk J Gastroenterol. 2005;16(4):183-7.
48. Sunbul M, Leblebicioglu H. Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey. World J Gastroenterol. 2005;11(13):1976-80.